CoChat

Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons

Open access
Chandrasekaran, Krish, Choi, Joungil, Arvas, Muhammed Ikbal, Salimian, Mohammad, Singh, Sujal, Xu, Su, Gullapalli, Rao P, Kristian, Tibor, Russell, James William · 2020 · International Journal of Molecular Sciences
Cited by 81

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD+ levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD+) levels to prevent dementia. We tested if the administration of the precursor of NAD+, nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD+ levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD+, activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21113756

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 60

  1. Grunblatt, 2011, The link between iron, metabolic syndrome, and Alzheimer’s disease, J. Neural Transm., 118, 371, 10.1007/s00702-010-0426-3 · DOI
  2. Ma, 2019, Neuroprotective effect of resveratrol via activation of Sirt1 signaling in a rat model of combined diabetes and Alzheimer’s disease, Front. Neurosci., 13, 1400, 10.3389/fnins.2019.01400 · DOI
  3. Zhou, 2018, Mitochondrial perturbation contributing to Cognitive Decline in Streptozotocin-Induced Type 1 Diabetic Rats, Cell Physiol. Biochem., 46, 1668, 10.1159/000489243 · doi:10.1159/000489243
  4. Cardoso, 2010, Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia, Biochim. Biophys. Acta, 1802, 942, 10.1016/j.bbadis.2010.07.001 · DOI
  5. Muriach, 2014, Diabetes and the brain: Oxidative stress, inflammation, and autophagy, Oxid. Med. Cell Longev., 2014, 102158, 10.1155/2014/102158 · DOI · Paper page
  6. Balonga, 2013, Mitochondrial dysfunction in brain cortex mitochondria of STZ-diabetic rats: Effect of l-Arginine, Neurochem. Res., 38, 2570, 10.1007/s11064-013-1172-3 · DOI
  7. Salceda, 2018, Mitochondrial activity in different regions of the brain at the onset of streptozotocin-induced diabetes in rats, Mol. Biol. Rep., 45, 871, 10.1007/s11033-018-4233-5 · DOI
  8. Butterfield, 2014, Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain, Biochim. Biophys. Acta, 1842, 1693, 10.1016/j.bbadis.2014.06.010 · DOI · Paper page
  9. Zhang, 2015, Region-specific cerebral metabolic alterations in streptozotocin-induced type 1 diabetic rats: An in vivo proton magnetic resonance spectroscopy study, J. Cereb. Blood Flow Metab., 35, 1738, 10.1038/jcbfm.2015.111 · DOI
  10. Jin, 2016, Effects of oxidative stress on hyperglycaemia-induced brain malformations in a diabetes mouse model, Exp. Cell Res., 347, 201, 10.1016/j.yexcr.2016.08.002 · DOI
  11. Yang, 2013, Long-term streptozotocin-induced diabetes in rats leads to severe damage of brain blood vessels and neurons via enhanced oxidative stress, Mol. Med. Rep., 7, 431, 10.3892/mmr.2012.1227 · DOI
  12. Zhao, 2016, Changes in neurons and synapses in hippocampus of streptozotocin-induced type 1 diabetes rats: A stereological investigation, Anat. Rec., 299, 1174, 10.1002/ar.23344 · DOI
  13. Belenky, 2007, NAD+ metabolism in health and disease, Trends Biochem. Sci., 32, 12, 10.1016/j.tibs.2006.11.006 · DOI · Paper page
  14. Osterloh, 2012, dSarm/Sarm1 is required for activation of an injury-induced axon death pathway, Science, 337, 481, 10.1126/science.1223899 · DOI · Paper page
  15. Geisler, 2016, Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice, Brain, 139, 3092, 10.1093/brain/aww251 · DOI · Paper page
  16. Turkiew, 2017, Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy, J. Peripher. Nerv. Syst., 22, 162, 10.1111/jns.12219 · DOI · Paper page
  17. Sasaki, 2019, Metabolic aspects of neuronal degeneration: From a NAD(+) point of view, Neurosci. Res., 139, 9, 10.1016/j.neures.2018.07.001 · DOI
  18. Bogan, 2008, Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition, Annu. Rev. Nutr., 28, 115, 10.1146/annurev.nutr.28.061807.155443 · DOI · Paper page
  19. Rodgers, 2008, Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways, FEBS Lett., 582, 46, 10.1016/j.febslet.2007.11.034 · DOI · Paper page
  20. Dominy, 2010, Nutrient-dependent regulation of PGC-1alpha’s acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5, Biochim. Biophys. Acta, 1804, 1676, 10.1016/j.bbapap.2009.11.023 · DOI · Paper page
  21. Brunet, 2004, Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase, Science, 303, 2011, 10.1126/science.1094637 · DOI · Paper page
  22. Vaziri, 2001, hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase, Cell, 107, 149, 10.1016/S0092-8674(01)00527-X · DOI · Paper page
  23. Tanner, 2000, Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose, Proc. Natl. Acad. Sci. USA, 97, 14178, 10.1073/pnas.250422697 · DOI · Paper page
  24. Jackson, 2003, Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases, J. Biol. Chem., 278, 50985, 10.1074/jbc.M306552200 · DOI · Paper page
  25. Chalkiadaki, 2012, Sirtuins mediate mammalian metabolic responses to nutrient availability, Nat. Rev. Endocrinol., 8, 287, 10.1038/nrendo.2011.225 · DOI · Paper page
  26. Lagouge, 2006, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, 127, 1109, 10.1016/j.cell.2006.11.013 · DOI · Paper page
  27. Choi, 2014, Brain diabetic neurodegeneration segregates with low intrinsic aerobic capacity, Ann. Clin. Transl. Neurol., 1, 589, 10.1002/acn3.86 · DOI · Paper page
  28. Wiegers, 2019, Elevated brain glutamate levels in type 1 diabetes: Correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status, Diabetologia, 62, 1065, 10.1007/s00125-019-4862-9 · DOI
  29. Zhao, 2018, Metabolomic analysis identifies lactate as an important pathogenic factor in diabetes-associated cognitive decline rats, Mol. Cell Proteomics, 17, 2335, 10.1074/mcp.RA118.000690 · DOI
  30. Golub, 2015, Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration, Front. Aging Neurosci., 7, 196, 10.3389/fnagi.2015.00196 · DOI
  31. Li, 2013, Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3, Mol. Neurobiol., 48, 490, 10.1007/s12035-013-8437-3 · DOI
  32. Chandrasekaran, 2019, Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy, Brain, 142, 3737, 10.1093/brain/awz324 · DOI
  33. Smith, 2012, Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes, Brain, 135, 1751, 10.1093/brain/aws097 · DOI · Paper page
  34. Klimova, 2020, NAD(+) precursor modulates post-ischemic mitochondrial fragmentation and reactive oxygen species generation via SIRT3 dependent mechanisms, Exp. Neurol., 325, 113144, 10.1016/j.expneurol.2019.113144 · DOI
  35. Lin, 2016, NAMPT-mediated NAD(+) biosynthesis is essential for vision in mice, Cell Rep., 17, 69, 10.1016/j.celrep.2016.08.073 · DOI · Paper page
  36. Klimova, 2019, Multi-targeted effect of nicotinamide mononucleotide on brain bioenergetic metabolism, Neurochem. Res., 44, 2280, 10.1007/s11064-019-02729-0 · DOI
  37. Long, A.N., Owens, K., Schlappal, A.E., Kristian, T., Fishman, P.S., and Schuh, R.A. (2015). Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol., 15. · DOI · Paper page
  38. Park, 2016, Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia, Neurobiol. Dis., 95, 102, 10.1016/j.nbd.2016.07.018 · DOI · Paper page
  39. Mittal, 2016, Shared links between type 2 diabetes mellitus and Alzheimer’s disease: A review, Diabetes Metab. Syndr., 10, S144, 10.1016/j.dsx.2016.01.021 · DOI
  40. Backes, 2016, Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning, Medicine, 95, e4803, 10.1097/MD.0000000000004803 · DOI
  41. Dugan, 1994, Excitotoxicity, free radicals, and cell membrane changes, Ann. Neurol., 35, S17, 10.1002/ana.410350707 · DOI · Paper page
  42. Alkadhi, 2019, Cellular and molecular differences between area CA1 and the dentate gyrus of the hippocampus, Mol. Neurobiol., 56, 6566, 10.1007/s12035-019-1541-2 · DOI
  43. Sherwin, 2003, Metabolic parameters of epilepsy: Adjuncts to established antiepileptic drug therapy, Neurochem. Res., 28, 353, 10.1023/A:1022433421761 · DOI
  44. Martinez, 2016, Metabolism of N-acetyl-L-aspartate: Its diagnostic and prognostic value, Rev. Neurol., 62, 361
  45. Moffett, 2013, N-Acetylaspartate reductions in brain injury: Impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation, Front. Neuroenergetics, 5, 11, 10.3389/fnene.2013.00011 · DOI · Paper page
  46. Geddes, 2003, Susceptibility of hippocampal neurons to mechanically induced injury, Exp. Neurol., 184, 420, 10.1016/S0014-4886(03)00254-1 · DOI
  47. Lin, 1998, Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: Microglial, astrocytic and endothelial alterations, Acta Neuropathol., 96, 610, 10.1007/s004010050942 · DOI
  48. Eichenbaum, 2000, Hippocampus: Mapping or memory?, Curr. Biol., 10, R785, 10.1016/S0960-9822(00)00763-6 · DOI · Paper page
  49. Ho, 2013, Effects of diabetes on hippocampal neurogenesis: Links to cognition and depression, Neurosci. Biobehav. Rev., 37, 1346, 10.1016/j.neubiorev.2013.03.010 · DOI · Paper page
  50. Trudeau, 2004, Hippocampal synaptic plasticity and glutamate receptor regulation: Influences of diabetes mellitus, Eur. J. Pharmacol., 490, 177, 10.1016/j.ejphar.2004.02.055 · DOI · Paper page
  51. Sansbury, 2011, Bioenergetic function in cardiovascular cells: The importance of the reserve capacity and its biological regulation, Chem. Biol. Interact., 191, 288, 10.1016/j.cbi.2010.12.002 · DOI · Paper page
  52. Xu, 2018, Brain SIRT1 mediates metabolic homeostasis and neuroprotection, Front. Endocrinol., 9, 702, 10.3389/fendo.2018.00702 · DOI
  53. Sun, 2017, The E3 ubiquitin ligase NEDD4 is an LC3-interactive protein and regulates autophagy, Autophagy, 13, 522, 10.1080/15548627.2016.1268301 · DOI
  54. Camera, 2016, Learning, memory and long-term potentiation are altered in Nedd4 heterozygous mice, Behav. Brain Res., 303, 176, 10.1016/j.bbr.2016.01.054 · DOI
  55. DiAntonio, 2010, Nedd4 branches out, Neuron, 65, 293, 10.1016/j.neuron.2010.01.028 · DOI
  56. Liang, 2014, Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS, Bioanalysis, 6, 1445, 10.4155/bio.14.8 · DOI
  57. Kristian, 2011, Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection, J. Neurosci. Res., 89, 1946, 10.1002/jnr.22626 · DOI · Paper page
  58. Owens, 2013, Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury, Transl. Stroke Res., 4, 618, 10.1007/s12975-013-0278-x · DOI
  59. Anjaneyulu, 2008, Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy, Exp. Neurol., 211, 469, 10.1016/j.expneurol.2008.02.011 · DOI
  60. Russell, 2008, Oxidative injury and neuropathy in diabetes and impaired glucose tolerance, Neurobiol. Dis., 30, 420, 10.1016/j.nbd.2008.02.013 · DOI

Cited by

See all 81

Metadata

Authors
Chandrasekaran, K., Choi, J., Arvas, M. I., Salimian, M., Singh, S., Xu, S., Gullapalli, R. P., Kristian, T., & Russell, J. W.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-05-26
Volume
21
Issue
11
Pages
3756
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3028677469
Cited by
81
References
16
FWCI
5.86
Type
journal article
Language
en
Open access
gold
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK107007-01A1)
  • Office of Research Development, Department of Veterans Affairs (101RX001030, BX000917 (T.K.))
  • Atlantic Nutrition Obesity Research Center, grant P30, NIDDK, NIH (DK072488)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.